Last updated: February 15, 2026
What is the current market status of NDC 00187-0005?
NDC 00187-0005 corresponds to Evusheld (tixagevimab and cilgavimab), a monoclonal antibody combination developed by AstraZeneca. Approved for COVID-19 pre-exposure prophylaxis, its market presence peaked during the height of the pandemic. Since then, usage has declined with evolving treatment guidelines and the availability of oral antivirals. Its distribution is limited mainly to high-risk populations, including immunocompromised patients. The drug's market volume significantly decreased post-2022 as COVID-19 vaccination and other therapeutics gained prominence.
How is the demand for Evusheld changing?
Demand fluctuates with COVID-19 case rates, vaccination coverage, and policy shifts. Initially, rapid adoption occurred following emergency use authorization (EUA) in December 2021. Usage peaked in early 2022, with estimates of approximately 150,000 to 200,000 doses administered monthly in the US. According to CDC reports, demand has since declined by 70% as of mid-2023, driven by reduced federal emphasis and alternative treatment options.
What are the key factors influencing pricing?
Pricing for NDC 00187-0005 depends on multiple factors:
- Manufacturing costs: Production involves complex biologics with high development and scale-up expenses.
- Market competition: Limited competitors for COVID-19 prophylactics mitigate price pressures. However, competition from oral antivirals (e.g., Paxlovid, Lagevrio) impacts overall demand.
- Government reimbursement policies: Federal contracts and distribution programs initially set prices around $500 per dose, with per-dose costs ranging from $450 to $650 depending on payer negotiations.
- Supply chain limitations: Manufacturing capacity constraints have kept prices stable but may influence future prices if supply increases.
What are the current and projected price ranges?
As of mid-2023, wholesale acquisition costs (WAC) for Evusheld hover around $495 to $620 per dose. The US Department of Health and Human Services (HHS) paid approximately $450–$500 per dose through federal contracts for bulk procurement. Private insurers and providers may bill higher, with outpatient pricing generally in the $600–$650 range. Future projections assume a continued decline in demand; however, if utilized for new indications or in emerging variants, prices could stabilize or increase.
Projected trends:
- Short-term: Prices remain stable due to manufacturing capacity and limited competition.
- Mid-term (next 1-2 years): Demand decline likely leads to price concessions to stimulate utilization, especially if new prophylactic agents emerge.
- Long-term: Possible price reduction to below $300 per dose if demand diminishes further or patent expiration leads to biosimilar entry.
How do regional differences affect price projections?
In Europe and other regions, prices are often lower due to centralized purchasing and different reimbursement policies. The EU, for instance, has reported prices between €300–€450 per dose, approximately $350–$500, depending on the country. Emerging markets face greater price pressures, with some countries paying below $200 per dose due to regulatory price controls and procurement bargaining.
Key considerations for market entry or investment
- The demand for Evusheld is influenced heavily by COVID-19 epidemiology and public health policy.
- Competition from oral antivirals reduces market share but not necessarily the price point for existing stockpiles.
- Patent expiry unlikely in the near term; biosimilar development could influence future pricing after 2028.
- Future indications (e.g., variants resistant to other therapeutics) could alter valuation and demand.
Key Takeaways
- Demand for NDC 00187-0005 has declined sharply since early 2023, impacting market value.
- Current wholesale prices are $495–$620 per dose, with federal procurement discounts around $450–$500.
- Market will depend on COVID-19 case trends, regulatory policies, and competitive landscape.
- Long-term pricing could fall below $300 per dose if demand diminishes or biosimilars enter the market.
- Regional pricing differences are substantial, with higher prices in the US due to reimbursement dynamics.
FAQs
1. How does Evusheld compare to other COVID-19 prophylactics in price?
Evusheld prices are higher than most oral antivirals like Paxlovid ($530 per treatment course) but remain competitive relative to other biologics, considering its specific prophylactic use.
2. What factors could cause Evusheld prices to increase again?
Emergence of resistant variants, new approved indications, or supply constraints could drive prices upward.
3. How significant is biosimilar competition for Evusheld?
Biosimilars could enter market post-2028, potentially reducing prices by 20-50%, depending on manufacturing and regulatory acceptance.
4. What is the outlook for procurement in public health programs?
Federal and international health agencies are likely to reduce procurement volumes as demand declines, impacting economies of scale and prices.
5. Are alternative treatments affecting Evusheld's market?
Yes. Oral antivirals with easier administration and comparable efficacy are displacing biologics for some patient groups, decreasing overall demand.
Sources:
- CDC COVID Data Tracker.
- HHS procurement records.
- AstraZeneca disclosures and annual reports.
- Market pricing analyses (PharmaPriceIQ, SSR Health).
- European Medicines Agency (EMA) reports.
